Systematic Reviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Dec 15, 2022; 13(12): 1168-1183
Published online Dec 15, 2022. doi: 10.4239/wjd.v13.i12.1168
Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review
Viswanathan Mohan, Subhash Wangnoo, Sambit Das, Rajnish Dhediya, Kumar Gaurav
Viswanathan Mohan, Department of Diabetes, Madras Diabetes Research Foundation & Dr Mohan’s Diabetes Specialties Centre, Chennai 600086, Tamil Nadu, India
Subhash Wangnoo, Department of Diabetes, Apollo Hospital Education and Research Foundation, New Delhi 110001, India
Sambit Das, Department of Endocrinology, Endeavour Clinics, Bhubaneswar 750017, India
Rajnish Dhediya, Kumar Gaurav, Medical Affairs, Dr. Reddy’s Laboratories Ltd, Hyderabad 500016, India
Author contributions: Mohan V, Wangnoo S, Das S, Dhediya R and Gaurav K read and approved the final manuscript; all authors contributed equally.
Conflict-of-interest statement: There are no conflicts of interest to report.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rajnish Dhediya, MBBS, MD, Medical Affairs, Dr. Reddy’s Laboratories Ltd, 7-1-27 Ameerpet, Hyderabad 500016, India. rajnishd@drreddys.com
Received: July 20, 2022
Peer-review started: July 20, 2022
First decision: September 4, 2022
Revised: September 20, 2022
Accepted: October 27, 2022
Article in press: October 27, 2022
Published online: December 15, 2022
Core Tip

Core Tip: This systematic review showed the lack of high-quality evidence and head-to head trials comparing the cardiovascular safety and hypoglycemia risk of gliclazide (a sulfonylurea) vs linagliptin (dipeptidyl peptidase-4 inhibitor) in adults with type 2 diabetes and no cardiovascular disease. While dipeptidyl peptidase-4 inhibitors have been proven to be cardiovascular neutral, sulfonylureas like gliclazide are commonly prescribed and recommended glucose-lowering drugs in low resource settings. Hence, it is important to establish the cardiovascular safety and hypoglycemia risk of gliclazide vs linagliptin to highlight that gliclazide may be a cost-effective yet safe treatment option for patients with type 2 diabetes.